产品说明
应用
L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.
包装
5, 25 mg in glass bottle
生化/生理作用
L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects.
PPARβ (PPARδ) selective agonist.
特点和优势
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
经验(实验)分子式 | C22H26O7 |
分子量 | 402.44 |
MDL编号 | MFCD04974501 |
PubChem化学物质编号 | 24278477 |
NACRES | NA.77 |
产品性质
质量水平 | 100 |
测定 | ≥98% (HPLC) |
形式 | powder |
储存条件 | protect from light under inert gas |
颜色 | off-white |
mp | 127-128 ℃ (lit.) |
溶解性 | DMSO: >10 mg/mL |
创始人 | GlaxoSmithKline |
储存温度 | 2-8℃ |
SMILES string | CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O |
InChI | 1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25) |
InChI key | HBBVCKCCQCQCTJ-UHFFFAOYSA-N |
Gene Information | human ... PPARD(5467) |
安全信息
储存分类代码 | 13 - Non Combustible Solids |
WGK | WGK 3 |
闪点(F) | Not applicable |
闪点(C) | Not applicable |
个人防护装备 | Eyeshields, Gloves, type N95 (US) |